{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T20:19:59Z","timestamp":1771618799774,"version":"3.50.1"},"reference-count":50,"publisher":"Begell House","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>&lt;b&gt;Background:&lt;\/b&gt; Ursolic acid (UA) and Rosuvastatin (RST) improves diabetic nephropathy (DN). However, the combination therapy of UA and RST on DN and its possible mechanism requires exploration.\n\n&lt;b&gt;Methods:&lt;\/b&gt; Streptozotocin (STZ)-induced DN model cells were treated with UA and RST alone or in combination. Cell viability and apoptosis were assessed using Cell Counting Kit-8 (CCK-8), flow cytometry, and TUNEL staining. The inflammation-related factors' release was examined by enzyme linked immunosorbent assay (ELISA). Potential mechanism was analyzed through network pharmacology. The reactive oxygen species (ROS) accumulation was detected using flow cytometry. The levels of superoxide dismutase (SOD), malondialdehyde (MDA), and catalase (CAT) were measured using commercial reagent kits.\n\n&lt;b&gt;Results:&lt;\/b&gt; UA and RST increased viability while reducing apoptosis of STZ-induced cells. UA and RST suppressed the release of inflammation-related factors in STZ-induced cells. Through network pharmacology analysis, the inflammation and oxidative stress were thought to be implicated in the treatment of UA and RST in DN. UA and RST downregulated ROS and MDA while upregulating SOD and CAT in STZ-induced cells. Compared with RST and UA used individually, their combination showed a more potent effect in increasing viability, mitigating apoptosis, and suppressing the inflammation and oxidative stress in STZ-induced cells.\n\n&lt;b&gt;Conclusion: &lt;\/b&gt;Combined UA and RST therapy ameliorated the inflammation and oxidative stress in DN model cells, providing the theoretical basis for pharmacological research of DN.<\/p>","DOI":"10.1615\/critrevimmunol.2026061077","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:29:41Z","timestamp":1767630581000},"page":"59-72","source":"Crossref","is-referenced-by-count":0,"title":["Combined Ursolic Acid and Rosuvastatin Treatment Mitigates Inflammation and Oxidative Stress in Diabetic Nephropathy Model Cells"],"prefix":"10.1615","volume":"46","author":[{"given":"Yijing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengli","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Jin Q, Liu T, Qiao Y, Liu D, Yang L, Mao H, Ma F, Wang Y, Peng L, Zhan Y. Oxidative stress and inflammation in diabetic nephropathy: Role of polyphenols. Front Immunol. 2023;14:1185317.","DOI":"10.3389\/fimmu.2023.1185317"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Li X, Lu L, Hou W, Huang T, Chen X, Qi J, Zhao Y, Zhu M. Epigenetics in the pathogenesis of diabetic nephropathy. Acta Biochim Biophys Sin. 2022;54(2):163-72.","DOI":"10.3724\/abbs.2021016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Guo J, Jiang Z, Xia Y, Wang H, Tang Q, Meng B. The association between statin use and diabetic nephropathy in US adults: Data from NHANES 2005-2018. Front Endocrinol. 2024;15:1381746.","DOI":"10.3389\/fendo.2024.1381746"},{"key":"5","doi-asserted-by":"crossref","unstructured":"VR ALBVR, Tan SH, Candasamy M, Bhattamisra SK. Diabetic nephropathy: An update on pathogenesis and drug development. Diabetes Metab Syndr. 2019;13(1):754-62.","DOI":"10.1016\/j.dsx.2018.11.054"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Dwivedi S, Sikarwar MS. Diabetic nephropathy: Pathogenesis, mechanisms, and therapeutic strategies. Horm Metab Res. 2025;57(1):7-17.","DOI":"10.1055\/a-2435-8264"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Zhu L, Ding M, Liu L, Yuan P, Shao T, Liu C, Xi C, Han J, Zhou Y, Zhang D, Wang G. Burdock Fructooligosaccharide protects against diabetic nephropathy in mice by regulating Nrf2 signaling. Pharmacol Res Perspect. 2025;13(3):e70094.","DOI":"10.1002\/prp2.70094"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Khwaza V, Oyedeji OO, Aderibigbe BA. Ursolic acid-based derivatives as potential anti-cancer agents: An update. Int J Mol Sci. 2020;21(16).","DOI":"10.3390\/ijms21165920"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Mlala S, Oyedeji AO, Gondwe M, Oyedeji OO. Ursolic acid and its derivatives as bioactive agents. Molecules. 2019;24(15).","DOI":"10.3390\/molecules24152751"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Zheng Y, Zhao L, Xiong Z, Huang C, Yong Q, Fang D, Fu Y, Gu S, Chen C, Li J, Zhu Y, Liu J, Liu F, Li Y. Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024;30(3):449-67.","DOI":"10.3350\/cmh.2024.0047"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Chen L, Li F, Ni JH, Hao YX, Feng G, Shen XY, You Y. Ursolic acid alleviates lupus nephritis by suppressing SUMO1-mediated stabilization of NLRP3. Phytomedicine. 2024;130:155556.","DOI":"10.1016\/j.phymed.2024.155556"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Qiu L, Wang Y, Wang Y, Liu F, Deng S, Xue W, Wang Y. Ursolic acid ameliorated neuronal damage by restoring microglia-activated MMP\/TIMP imbalance in vitro. Drug Des Devel Ther. 2023;17:2481-93.","DOI":"10.2147\/DDDT.S411408"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Zou J, Lin J, Li C, Zhao R, Fan L, Yu J, Shao J. Ursolic acid in cancer treatment and metastatic chemoprevention: From synthesized derivatives to nanoformulations in preclinical studies. Curr Cancer Drug Targets. 2019;19(4): 245-56.","DOI":"10.2174\/1568009618666181016145940"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Liu HR, Ahmad N, Lv B, Li C. Advances in production and structural derivatization of the promising molecule ursolic acid. Biotechnol J. 2021;16(11):e2000657.","DOI":"10.1002\/biot.202000657"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Rong ZJ, Chen M, Cai HH, Liu GH, Chen JB, Wang H, Zhang ZW, Huang YL, Ni SF. Ursolic acid molecules dock MAPK1 to modulate gut microbiota diversity to reduce neuropathic pain. Neuropharmacology. 2024;252:109939.","DOI":"10.1016\/j.neuropharm.2024.109939"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Mei H, Jing T, Liu H, Liu Y, Zhu X, Wang J, Xu L. Ursolic acid alleviates mitotic catastrophe in podocyte by inhibiting autophagic P62 accumulation in diabetic nephropathy. Int J Biol Sci. 2024;20(9):3317-33.","DOI":"10.7150\/ijbs.94096"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Shimm DS, Doppke KP, Leong JC, Gregory E, Dosoretz DE. Variation in the lung inhomogeneity correction factor with beam energy. Clinical implications. Acta Radiol Oncol. 1985;24(5):407-10.","DOI":"10.3109\/02841868509134409"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Wu X, Li H, Wan Z, Wang R, Liu J, Liu Q, Zhao H, Wang Z, Zhang H, Guo H, Qi C, Jiao X, Li X. The combination of ursolic acid and empagliflozin relieves diabetic nephropathy by reducing inflammation, oxidative stress and renal fibrosis. Biomed Pharmacother. 2021;144:112267.","DOI":"10.1016\/j.biopha.2021.112267"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs. 2002;62(14):2075-85; discussion 86-7.","DOI":"10.2165\/00003495-200262140-00008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Barrios V, Escobar C. Fixed-dose combination of rosuvastatin and ezetimibe: Treating hypercholesteremia according to cardiovascular risk. Expert Rev Clin Pharmacol. 2021;14(7):793-806.","DOI":"10.1080\/17512433.2021.1925539"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC. The efficacy and safety of moderate-intensity rosuvastatin with ezetimibe versus high-intensity rosuvastatin in high atherosclerotic cardiovascular disease risk patients with type 2 diabetes mellitus: A randomized, multicenter, open, parallel, phase 4 study. Diabetes Metab J. 2023;47(6):818-25.","DOI":"10.4093\/dmj.2023.0171"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Nishikido T, Oyama J, Keida T, Ohira H, Node K. Highdose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The standard versus high-dose therapy with Rosuvastatin for lipiD lowering (SARD) trial. J Cardiol. 2016;67(4):340-6.","DOI":"10.1016\/j.jjcc.2015.05.017"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Boczar KE, Faller E, Zeng W, Wang J, Small GR, Corrales-Medina VF, deKemp RA, Ward NC, Beanlands RSB, MacPherson P, Dwivedi G. Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study. J Nucl Cardiol. 2022;29(6):3057-68.","DOI":"10.1007\/s12350-021-02830-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Saadat S, Boskabady MH. Anti-inflammatory and antioxidant effects of rosuvastatin on asthmatic, hyperlipidemic, and asthmatic-hyperlipidemic rat models. Inflammation. 2021;44(6):2279-90.","DOI":"10.1007\/s10753-021-01499-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Heeba GH, Ali MAM, El-Sheikh AAK. Rosuvastatin induces renal HO-1 activity and expression levels as a main protective mechanism against STZ-induced diabetic nephropathy. Medicina. 2022;58(3).","DOI":"10.3390\/medicina58030425"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Wen JH, Xiong YQ. The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet. 2011;36(4):205-11.","DOI":"10.1007\/s13318-011-0048-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Dh HS, Sultana R, Prabhu A, S RP, Mohanto S, Subramaniyan V. Biomedicine and pharmacotherapeutic effectiveness of combinatorial atorvastatin and quercetin on diabetic nephropathy: An in vitro study. Biomed Pharmacother. 2024;174:116533.","DOI":"10.1016\/j.biopha.2024.116533"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Chen CH, Cheng CY, Chen YC, Sue YM, Hsu YH, Tsai WL, Chen TH. Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells. Eur J Pharmacol. 2013;700(1-3):65-73.","DOI":"10.1016\/j.ejphar.2012.12.017"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Feng Q, Yu X, Xie J, Liu F, Zhang X, Li S, Wang Y, Pan S, Liu D, Liu Z. Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4\/MyD88\/NF-kB and PI3K\/AKT\/GSK3B signaling pathways. Phytomedicine. 2025;136:156314.","DOI":"10.1016\/j.phymed.2024.156314"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Jiang WJ, Xu CT, Du CL, Dong JH, Xu SB, Hu BF, Feng R, Zang DD, Meng XM, Huang C, Li J, Ma TT. Tubular epithelial cell-to-macrophage communication forms a negative feedback loop via extracellular vesicle transfer to promote renal inflammation and apoptosis in diabetic nephropathy. Theranostics. 2022;12(1):324-39.","DOI":"10.7150\/thno.63735"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Yan M, Li W, Wei R, Li S, Liu Y, Huang Y, Zhang Y, Lu Z, Lu Q. Identification of pyroptosis-related genes and potential drugs in diabetic nephropathy. J Transl Med. 2023;21(1):490.","DOI":"10.1186\/s12967-023-04350-w"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Guo M, Gao J, Jiang L, Dai Y. Astragalus polysaccharide ameliorates renal inflammatory responses in a diabetic nephropathy by suppressing the TLR4\/NF-kB pthway. Drug Des Dev Ther. 2023;17:2107-18.","DOI":"10.2147\/DDDT.S411211"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Qiu D, Song S, Chen N, Bian Y, Yuan C, Zhang W, Duan H, Shi Y. NQO1 alleviates renal fibrosis by inhibiting the TLR4\/NF-kB and TGF-B\/Smad signaling pathways in diabetic nephropathy. Cell Signal. 2023;108:110712.","DOI":"10.1016\/j.cellsig.2023.110712"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Quan Y, Su P, Shangguan C, Hao H, Yue L, Chen C. Bergenin ameliorates diabetic nephropathy in C57BL\/6 J mice by TLR4\/MyD88\/NF-kB signalling pathway regulation. Toxicol Appl Pharmacol. 2023;475:116633.","DOI":"10.1016\/j.taap.2023.116633"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Vringer E, Tait SWG. Mitochondria and cell death-associated inflammation. Cell Death Diff. 2023;30(2):304-12.","DOI":"10.1038\/s41418-022-01094-w"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Xie G, Chen H, He C, Hu S, Xiao X, Luo Q. The dysregulation of miRNAs in epilepsy and their regulatory role in inflammation and apoptosis. Funct Integr Genom. 2023;23(3):287.","DOI":"10.1007\/s10142-023-01220-y"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Feng L, Chen C, Xiong X, Wang X, Li X, Kuang Q, Wei X, Gao L, Niu X, Li Q, Yang J, Li L, Luo P. PS-MPs promotes the progression of inflammation and fibrosis in diabetic nephropathy through NLRP3\/Caspase-1 and TGF-B1\/Smad2\/3 signaling pathways. Ecotoxicol Environ Saf. 2024;273:116102.","DOI":"10.1016\/j.ecoenv.2024.116102"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Yang F, Zhang Z, Zhang L. Bisacurone attenuates diabetic nephropathy by ameliorating oxidative stress, inflammation and apoptosis in rats. Hum Exp Toxicol. 2022;41:9603271221143713.","DOI":"10.1177\/09603271221143713"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Lei P, Li Z, Hua Q, Song P, Gao L, Zhou L, Cai Q. Ursolic acid alleviates neuroinflammation after intracerebral hemorrhage by mediating microglial pyroptosis via the NF-\u00ce\u00baB\/NLRP3\/GSDMD pathway. Int J Mol Sci. 2023; 24(19).","DOI":"10.3390\/ijms241914771"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Bielecka E, Zubrzycka N, Marzec K, Maksylewicz A, Sochalska M, Kulawik-Pi\u00f3ro A, Laso\u0144 E, Sliwa K, Malinowska M, Sikora E, Nowak K, Miastkowska M, Kantyka T. Ursolic acid formulations effectively induce apoptosis and limit inflammation in the psoriasis models in vitro. Biomedicines. 2024;12(4).","DOI":"10.3390\/biomedicines12040732"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res. 2016;107:1-18.","DOI":"10.1016\/j.phrs.2016.02.012"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Sultan F, Kaur R, Tarfain NU, Mir AH, Dumka VK, Sharma SK, Singh Saini SP. Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2\/Bax, iNOS, and TNF-a expressions affecting oxidative\/nitrosative stress and inflammation. Hum Exp Toxicol. 2022;41:9603271211066065.","DOI":"10.1177\/09603271211066065"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Matsuo S, Saiki Y, Adachi O, Kawamoto S, Fukushige S, Horii A, Saiki Y. Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension. J Thorac Cardiovasc Surg. 2015;149(3):902-9.","DOI":"10.1016\/j.jtcvs.2014.10.030"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Yeni Y, Cicek B, Hacimuftuoglu A, Ozkaraca M, Lacin BB. Protective effect of HMG-CoA reductase inhibitor rosuvastatin on doxorubicin-induced cognitive impairment, oxidative stress and neuroinflammation: Possible role of CREB, ERK1\/2, and BDNF. J Neuroimmune Pharmacol. 2025;20(1):53.","DOI":"10.1007\/s11481-025-10213-6"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Cao Y, Chen Z, Jia J, Chen A, Gao Y, Qian J, Ge J. Rosuvastatin alleviates coronary microembolization-induced cardiac injury by suppressing Nox2-induced ROS overproduction and myocardial apoptosis. Cardiovasc Toxicol. 2022;22(4):341-51.","DOI":"10.1007\/s12012-021-09716-4"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Xu M, Zhou H, Hu P, Pan Y, Wang S, Liu L, Liu X. Identification and validation of immune and oxidative stress-related diagnostic markers for diabetic nephropathy by WGCNA and machine learning. Front Immunol. 2023;14:1084531.","DOI":"10.3389\/fimmu.2023.1084531"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Wang Y, Long L, Chen M, Li J. Oxidative stress mediated by the NOX2\/ROS\/NF-\u00ce\u00baB signaling axis is involved in rosacea. Arch Dermatol Res. 2025;317(1):505.","DOI":"10.1007\/s00403-025-03898-5"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Zeng G, Li J, Wang Y, Su J, Lu Z, Zhang F, Ding W. Polystyrene microplastic-induced oxidative stress triggers intestinal barrier dysfunction via the NF-kB\/NLRP3\/IL-1B\/MCLK pathway. Environ Pollut. 2024;345:123473.","DOI":"10.1016\/j.envpol.2024.123473"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res. 2017;39(1):73-82.","DOI":"10.1080\/01616412.2016.1251711"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Zhan Y, Xu D, Tian Y, Qu X, Sheng M, Lin Y, Ke M, Jiang L, Xia Q, Kaldas FM, Farmer DG, Ke B. Novel role of macrophage TXNIP-mediated CYLD-NRF2-OASL1 axis in stress-induced liver inflammation and cell death. JHEP Rep. 2022;4(9):100532.","DOI":"10.1016\/j.jhepr.2022.100532"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018-28.","DOI":"10.5551\/jat.9084"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/1378c4ab18033f7a\/CRI-61077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:46:07Z","timestamp":1771616767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,0184364166ea9892,1378c4ab18033f7a.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2026061077","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}